1	Limited induction of lung-resident memory T cell responses against
2	SARS-CoV-2 by mRNA vaccination
3	
4	Daan K.J. Pieren ¹ , Sebastián G. Kuguel ¹ , Joel Rosado ² , Alba G. Robles ¹ , Joan Rey-Cano ¹ , Cristina
5	Mancebo ¹ , Juliana Esperalba ⁴ , Vicenç Falcó ¹ , María J. Buzón ¹ , Meritxell Genescà ¹ *
6	
7	Affiliations
8	¹ Infectious Diseases Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital
9	Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129,
10	08035 Barcelona, Spain;
11	² Thoracic Surgery and Lung Transplantation Department, Vall d'Hebron Institut de Recerca (VHIR), Vall
12	d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129,
13	08035 Barcelona, Spain;
14 15	"Respiratory viruses Unit, Microbiology Department, Vali d Hebron Institut de Recerca (VHIR), Vali d'Hebron Heapitel Universiteri. Vali d'Hebron Pareclana Heapitel Campus, Dasseig Vali d'Hebron 110
15 16	129 08035 Barcelona Spain
17	*Correspondence: meritxell genesca@vbir org (M G)
18	Conceptingences miningencess Connects
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
32	
34	
35 35	
55	

1 SUMMARY

- 2 Resident memory T cells (T_{RM}) present at the respiratory tract may be essential to enhance early 3 SARS-CoV-2 viral clearance, thus limiting viral infection and disease. While long-term antigen 4 (Ag)-specific T_{RM} are detectable beyond 11 months in the lung of convalescent COVID-19 patients 5 after mild and severe infection¹, it is unknown if mRNA vaccination encoding for the SARS-CoV-6 2 S-protein can induce this frontline protection. We found that the frequency of CD4⁺ T cells 7 secreting interferon (IFN) γ in response to S-peptides was similar in the lung of mRNA-vaccinated 8 patients compared to convalescent-infected patients. However, in vaccinated patients, lung 9 responses presented less frequently a T_{RM} phenotype compared to convalescent infected 10 individuals and polyfunctional T_{RM} were virtually absent. Thus, a robust and wide T_{RM} response 11 established in convalescent-infected individuals may be advantageous in limiting disease if the 12 virus is not block by initial mechanisms of protection, such as neutralization. Still, mRNA vaccines 13 can induce modest responses within the lung parenchyma potentially contributing to the overall 14 disease control. 15
- 16

1 **MAIN**

2 The COVID-19 pandemic continues, and many countries face multiple resurgences. While 3 vaccines to limit SARS-CoV-2 infection rapidly emerged providing high protection from COVID-4 19, more insight into the mechanisms of protection induced by available vaccines is still needed. 5 The level of vaccine-induced neutralizing antibodies has been shown to correlate with protection 6 from symptomatic infection; however, predicted antibody-mediated vaccine efficacy declines over 7 time². Moreover, many viral variants of concern (VOC) can significantly evade humoral immunity, 8 vet cellular responses induced by vaccines show strong cross-protection against these variants³. 9 ⁴, supporting the idea that cellular responses largely contribute to disease control⁵. In fact, 10 preexisting cross-reactive memory T cells and early Nucleocapsid (N) responses against 11 coronaviruses are associated with protection from SARS-CoV-2 infection^{6,7}. Further, SARS-CoV-12 2 infection induces robust cellular immunity detectable beyond 10 months after infection in 13 peripheral blood⁸, and as T_{RM} in the lung¹, and the number of SARS-CoV-2-specific T_{RM} in the 14 lung correlates with clinical protection⁹. Vaccination against SARS-CoV-2 using BTN162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna) vaccines has been reported to induce CD4⁺ and 15 CD8⁺ T-cell responses in peripheral blood^{10, 11}. Moreover, the IFN_Y T-cell response to SARS-CoV-16 17 2 S-peptides, one of the main antiviral factors measured as a readout, further increased after 18 boosting¹¹. However, current studies only address vaccine-induced SARS-CoV-2 specific T-cell 19 responses in peripheral blood and whether mRNA vaccines also elicit SARS-CoV-2-specific long-20 term T_{RM} cells in the lung remains to be established.

21 To this end, we determined the presence of SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells 22 in 26 paired peripheral blood and lung cross-sectional samples from: I.) uninfected unvaccinated 23 individuals (Ctrl, n=5), II.) unvaccinated long-term SARS-CoV-2 convalescent individuals (Inf, 24 n=9, convalescent for a median of 304 days [183-320 IQR]), III.) uninfected and long-term two-25 dose vaccinated individuals (Vx2, n=7, a median of 206 days [184-234] after the second dose). 26 and IV.) uninfected and short-term three-dose vaccinated individuals (Vx3, n=5, a median of 52 27 days [42-54] after the third dose or boost). Patient characteristics are summarized in Extended 28 Table 1. In order to confirm the SARS-CoV-2 status of each patient, we analyzed total 29 immunoglobulin (Ig) or IgG levels against N and Spike (S) proteins respectively, which 30 discriminated Ctrl (negative for N and S). Inf patients (positive for N and S) and vaccinated groups 31 (negative for N and positive for S; Extended Table 1). Furthermore, the viral neutralization titer 32 was determined against the SARS-CoV-2 Omicron variant using a pseudovirus neutralization 33 assay and, as expected^{10, 11}, a positive correlation between neutralization and S-IgG titers was 34 detected (Spearman r = 0.72, P = 0.0016; Extended Data Fig.1a). In addition to the absence of

1 neutralization of the Omicron variant in plasma of the Ctrl group, 2 out of 7 patients (28%) in the 2 Inf group and from 1 out of 6 patients (17%) in the Vx2 group failed to neutralize the virus, whereas 3 all patients in the Vx3 group were able to neutralize this variant (Extended Table 1). The fact that 4 we mostly studied elderly patients could certainly determine the overall response and, indeed 5 there was a negative correlation between older age and neutralizing capacity for the Inf group 6 (Spearman r = -0.88, P = 0.01; Extended Data Fig.1b) and the same trend was observed for the 7 Vx2 group (Spearman r = - 0.72, P = 0.10; Extended Data Fig.1c). This relationship was less 8 evident between age and S-IgG titers (Extended Data Figs.1d, e), yet examples in larger cohorts 9 exist¹⁰. Instead, S-IgG titers from all groups negatively correlated with sample timing (Spearman 10 r = -0.61, P = 0.010; Extended Data Fig.1f), a correlation that was also observed for total lg against N in the Inf group (Spearman r = -0.88, P = 0.009; Extended Data Fig.1g), which agrees with 11 12 antibody titers decay^{10, 11, 12}.

To address cellular immune responses, we stimulated fresh peripheral blood mononuclear 13 14 cells (PBMC) and lung-derived cellular suspensions with overlapping Membrane (M), N and S 15 peptide pools and determined the intracellular expression of IFN_{γ}, interleukin (IL)-4, and IL-10, 16 along with the degranulation marker CD107a in CD4⁺ and CD8⁺ T cells (Extended Data Fig.2a), 17 as previously described¹. We found detectable circulating IFN_{γ}-secreting Ag-specific CD4⁺ T cells 18 responding to all proteins in the blood of Inf patients, which was significantly higher compared to 19 the Ctrl, Vx2, and Vx3 groups for M and N peptides (Fig. 1a, b). In contrast, for S peptides, the Inf 20 group only showed higher frequencies of IFN γ^+ CD4⁺ T cells compared to the Ctrl group, indicating 21 an increase induced by vaccination in the blood of Vx2 and Vx3 groups. However, only two Vx2 22 patients showed detectable frequencies of S-specific CD4⁺ T cells in blood, while recently boosted 23 Vx3 patients displayed an overall increase reaching statistical significance compared to the Ctrl 24 group (Fig. 1b). In contrast to CD4⁺ T cells, the frequencies of IFN γ^+ CD8⁺ T cells detected were 25 minimal for each of the groups against any of the proteins, including for the Vx groups against S 26 peptides (Fig. 1b). Expression of IL-4, IL-10, and CD107a by T cells showed, in general, high 27 variability, limiting the detection of differences (Extended Data Fig. 3). Nonetheless, S-specific 28 degranulating CD107a⁺ CD8⁺ T cells were overall more frequent in the Vx2 compared to the Ctrl 29 group (P = 0.046; Extended Data Fig. 3). Together, these data indicate that M, N, and S-peptide 30 specific IFN γ^+ CD4⁺ T cell responses can be readily detected in blood months after resolving 31 natural SARS-CoV-2 infection and that these responses require a recent mRNA vaccine booster-32 dose against SARS-CoV-2 to elicit similar frequencies against the S protein in vaccinated 33 individuals.

1 As reported previously¹, we here found that mild or severe natural infection with SARS-2 CoV-2 induced robust IFN γ^+ CD4⁺ T cells in the lung against M, N, and S peptides, detectable for 3 up to 12 months after infection (Fig. 2a, b). Interestingly, whereas M and N-specific IFN γ^+ CD4⁺ 4 T-cell frequencies were significantly higher in the Inf group compared to Ctrl or Vx groups, these 5 differences were not observed for S-specific responses (Figs. 2a, b). Vx2 and Vx3 groups showed 6 presence of S-specific IFN γ^+ CD4⁺ T cells in the lung in most patients and its frequency was 7 comparable to levels detected in Inf patients, although statistical significance was no reached 8 compared to the Ctrl group (Fig. 2b). In contrast to CD4⁺T cells, CD8⁺T cells producing IFN₇ after 9 stimulation with M, N, or S peptides was variable within each group and did not result in significant 10 differences between the groups, indicating that natural infection nor vaccination elicit a robust 11 IFN_γ positive CD8⁺ T cell response in the human lung (Fig. 2b). Furthermore, induction of lung 12 anti-SARS-CoV-2-specific T-cell responses involving expression of IL-4. IL-10, and CD107a did 13 not differ between groups (Extended Data Fig. 4a). Of note, in this tissue compartment, we 14 detected negative correlations between patient's age within the Inf group and the frequency of S-15 specific degranulating CD4⁺ and CD8⁺ T cells (Spearman r = -0.76, P = 0.024 and Spearman r = -0.76, P = 0.024 and Spearman r = -0.76, P = -0.76, 16 - 0.77, P = 0.020 respectively, Extended Data Fig. 4b).

17 When we compared the magnitude of S-specific T cells in paired blood and lung samples, 18 we found increased frequencies of IFN γ^+ CD4⁺ T cells in the lungs of patients from the Inf group 19 compared to blood (P=0.039, Fig. 2c). The same trend was observed for the Vx individuals, which 20 was close to significant if both groups were pooled (P = 0.054). In contrast, the CD8⁺ T-cell 21 compartment did not show clear differences between these two compartments (Fig. 2c), neither 22 any of the T-cell subsets for any other function, which were highly variable (Extended Data Fig. 23 5). Together our data shows that S-specific CD4⁺ T-cell responses are detectable in the lung of 24 uninfected vaccinated patients, indicating that mRNA vaccination against SARS-CoV-2 may elicit 25 tissue-localized protective T-cell responses already after the second mRNA vaccine dose.

26 Considering the presence of T_{RM} in the respiratory tract might provide a better correlate of 27 protection from disease in SARS-CoV-2 infected individuals^{1, 9}, we next analyzed expression of 28 CD69 and CD103 by lung SARS-CoV-2-specific CD4⁺ and CD8⁺T cells, which we classified as: 29 $CD69^{-}$ (non-T_{RM}), $CD69^{+}$ (T_{RM}) and a subset within $CD69^{+}$ cells expressing $CD103^{+}$ (T_{RM} $CD103^{+}$) 30 (Fig. 3a, Extended Data Fig. 2b for gating strategy). Of note, CD69⁺T cells showed down-31 regulation of T-bet in all groups (Extended Data Fig. 2b), which has been associated to tissue 32 residency¹. S-specific CD4⁺ T cells from the Inf group showed higher frequencies of IFN γ^+ cells 33 within the CD69⁺ and CD103⁺ T_{RM} phenotypes (Fig. 3a, b), with statistical significance reached 34 for the overall CD69⁺ T_{RM} fraction compared to the non- T_{RM} fraction. Furthermore, while no

1 significant differences were detected for CD103⁺ T_{RM} cells against S-peptides in any of the groups, 2 a trend was observed for CD4⁺ T-cell responses to M peptides and statistical significance was 3 reached for CD8⁺ T cells against N peptides compared to the non-T_{RM} fraction in the Inf group 4 (Extended Data Fig. 6a, b). Of note, a negative correlation was observed between IFN γ -secreting 5 S-specific CD8⁺ CD103⁺ T_{RM} cells and sample timing (Spearman r = - 0.82, P = 0.019 Extended 6 Data Fig. 6c). Similar to the Inf group, some patients in the Vx2 and Vx3 groups showed presence 7 of S-specific T_{RM} with or without CD103 expression in their lungs (Figs. 3a, b). However, this 8 response was highly heterogeneous and not statistically significant. These findings indicate that 9 mRNA vaccination against SARS-CoV-2 can induce S-specific T_{RM} in some, but not all individuals 10 and may also last long term after the second vaccination.

11 To better gain insight into the overall S-specific response by each group, including all 12 functions and considering lung-T_{RM} phenotypes, we represented S-specific CD4⁺ and CD8⁺ T cell 13 subsets as donut charts displaying the mean frequency of responses including all individuals 14 (responders and non-responders, Fig. 4, b). This way, a dominance of IFN_Y-secreting CD4⁺ T 15 cells was particularly associated to the two T_{RM} phenotypes in the Inf and, to a lesser extent, in 16 the Vx2 patients (Fig. 4a). Further, S-specific responses within non- T_{RM} and blood CD4⁺ T cells 17 were functionally similar and in general dominated by IFN_{γ} and IL-4 secretion (Fig. 4a). In 18 contrast, degranulation characterized the majority of lung S-specific CD8⁺ T cells from Inf 19 individuals (Fig. 4b), which correlated negatively with older age for the T_{RM} fractions (Spearman r 20 = -0.88, P = 0.006 for both CD103 positive and negative. Extended Data Fig. 6d). Degranulation 21 was also the major function in blood from the two Vx groups (Fig. 4b). Last, in general, CD8⁺ T-22 cell responses considering all functions were of higher magnitude in long-term Vx2 individuals, 23 reaching statistical significance for blood responses in comparison to the Ctrl group, as shown in 24 the adjoin graph on the right (Fig. 4b).

25 We previously detected a low but consistent polyfunctional IFN γ^+ CD107a⁺ T-cell response 26 mostly associated to the T_{RM} fraction in convalescent infected patients¹. We therefore investigated 27 whether mRNA vaccination against SARS-CoV-2 would also induce S-specific polyfunctional 28 responses in both compartments (Figs. 5a, b). Indeed, increased frequencies of polyfunctional 29 IFN_Y⁺CD107a⁺ CD4⁺ T cells were detected in blood from the Inf group against N peptides 30 compared to the Ctrl group, but not against M- and S-peptides. Interestingly, a trend towards 31 higher frequencies of S-specific polyfunctional CD4⁺ T cells was observed for the Vx3 group (Fig. 32 5a). Likewise, circulating polyfunctional S-specific CD8⁺ T cells were enhanced in Vx2 individuals 33 compared to Ctrl group (Fig. 5a). In fact, if Vx groups were pooled to increase sample size, then 34 both CD4⁺ and CD8⁺ T cells reached significance compared to Ctrl samples (P = 0.037 for CD4⁺

1 and P = 0.024 for CD8⁺). In addition, the frequency of polyfunctional IFN_Y⁺CD107a⁺ cells present 2 in total CD4⁺ and CD8⁺ T cells in the lung were only consistently increased in the Inf group against 3 N peptides compared to the Ctrl and Vx3 groups (Fig. 5b). Nevertheless, while a high degree of variability was observed among vaccinated patients, polyfunctional S-specific T cells were 4 5 detected in some individuals (Fig. 5b). Strikingly, S-specific CD4⁺ polyfunctional CD103⁺ T_{RM} cells 6 were virtually absent in the Vx2 and Vx3 groups, while being frequently present in the lungs of 7 patients from the Inf group (Extended data Fig. 7). Furthermore, the frequency of S-specific 8 polyfunctional CD4⁺T cells in the CD69⁺ T_{RM} cells was higher in the Inf group compared to the 9 Ctrl and Vx2 groups (Extended data Fig. 7). Together, these data indicate that both short- and 10 long-term vaccination do not induce S-specific IFN γ^+ CD107a⁺ CD103⁺ T_{RM} cells in the lung, which 11 may contribute to antiviral activity.

Last, considering the uniqueness of analyzing immune responses in paired blood and lung 12 13 parenchyma samples and recent studies detailing changes in T cell responses in infected 14 individuals already vaccinated and vice versa¹³, we highlight two patients that were discarded due 15 to not fitting inclusion criteria, yet bring interesting data to the study. HL174 was a patient in their 16 fifties who received the third mRNA-1273 vaccine boost and, five days after, tested positive by 17 PCR. We analyzed paired tissue samples 30 days after the boost/infection event (Extended Data 18 Fig. 8a). This patient had a neutralization titer of 1740 IU/mL against omicron, and had detectable 19 IgG and Ig titers against S and N proteins (>800 AU/mL and 1.23 index, respectively). When 20 comparing T-cell responses from blood and lung tissue, a much higher IFNy-response was 21 observed in the lung, in particular against the N protein, which already contained responding cells 22 with a T_{RM} phenotype (Extended Data Fig. 8b, c). In contrast, in blood, degranulation was 23 enhanced mostly against S but also M protein and some proportion of IL-10 secretion was 24 detected against all proteins (Extended Data Fig. 8b).

25 On the other hand, patient HL162, who was in their early seventies, was first infected 26 presenting a mild COVID-19 and, several months after, received three doses of the mRNA-1273 27 vaccine. In this case, we obtained samples 3.7 months after infection and another one 1.3 months 28 after the third dose (due to a second intervention for a lung carcinoma), which corresponded to a 29 year after initial infection, as shown (Extended Data Fig. 9a). Neither of these two time points 30 showed neutralization titers against omicron and the titers of IgG, instead of increasing after triple 31 vaccination, decreased from 156 to 0 index for the N protein and from 306.54 to 13.85 AU/mL for 32 S protein. The comparison of the tissue compartments after infection and after triple vaccination 33 evidenced a concomitant strong decrease in T-cell responses in blood and tissue (Extended Data 34 Figs. 9b, c, and Extended Data Fig. 10a, b). However, IFNγ-secreting SARS-CoV-2 T cells against

M and N proteins in the lung were better preserved from the original infection one year later than were responses against the S protein enhanced due to vaccination (Extended Data Fig. 9b, c, and Extended Data Fig. 10a, b). Thus, while the lower respiratory tract compartment more faithfully represented T_{RM} responses established already during the infection event one year earlier, responses in blood mostly vanished.

6 Comprehensive studies comparing the magnitude and duration of the T cell responses 7 indicate similar magnitude after dual vaccination and after natural SARS-CoV-2 infection^{5, 11, 13}. 8 However, these results may not hold if we consider that the magnitude, the functional profile and 9 even the duration of these responses in blood may not faithfully reflect responses in the 10 respiratory tract^{1, 7, 9, 14}. In fact, the individual comparison between these two compartments among the S-responding T cells from the different groups showed higher magnitude in the lung 11 12 than in the blood, but also a different profile. A key difference, and the main driver of our study, 13 was the establishment of long-term protection potentially mediated by T_{RM} after vaccination, since 14 longevity of SARS-CoV-2 T cell responses remains a critical question⁷. In principle, T_{RM} are 15 established by mucosal infection since Ag together with local signals promote the recruitment and 16 establishment of this memory response. In this sense, intramuscular vaccination with an 17 adenovector vaccine in mice did not induce SARS-CoV-2-specific T_{RM} in their lungs¹⁵. Thus, to 18 induce potent resident immunity, vaccine strategies may need to either use live-attenuated Ag or 19 employ mucosal routes. Consequently, the absence of vaccine induced S-specific T_{RM} could be 20 expected in infection-naïve individuals. Still, recent data shows that a secretory IgA response was 21 induced in ~30% of participants after two doses of a SARS-CoV-2 mRNA vaccine which, in 22 addition, may play an important role in protection against infection¹⁴. While we detected S-specific 23 IFN γ^+ CD4⁺ T cell responses in the lung of vaccinated individuals, the proportion of these cells in 24 the T_{RM} phenotype was modest, in particular if considering CD103 expression. Further, the 25 presence of polyfunctional IFN γ^+ CD107a⁺CD4⁺CD103⁺T_{RM} appeared to be restricted to the lungs 26 of convalescent-infected patients only. Yet, lung S-specific CD8⁺ T_{RM} presented similar overall 27 frequencies in vaccinated individuals when considering all functions. In fact, overall CD8⁺ T cell 28 response, which was in general low and dominated by degranulation, appeared enhanced in 29 some but not all vaccinated patients. Considering the putative protective role of CD8⁺ T cells 30 observed in animal models¹⁶, our results for these vaccinated individuals are certainly 31 encouraging.

Another difference in the comparison of the cellular immunity between SARS-CoV-2infected convalescent and uninfected-vaccinated individuals is the broader and, potentially stronger, response induced by symptomatic infection. This is partially manifested by the fact that,

1 when comparing the overall magnitude, responses against M and N peptides are frequently higher than S peptides^{1, 17, 18} ¹⁹. Of note, disease severity may impact both, the magnitude and function 2 of the T cell response against the different proteins^{1, 20, 21}. In addition, among other factors, age 3 4 also influences the magnitude and duration of immune responses in distinct tissue compartments, 5 even the establishment of T_{RM}^{22} , a factor that influenced the frequency of degranulation in the 6 lung of our Inf patients, including within the T_{RM} fraction. Yet advanced age will also limit the 7 immune response to vaccination²³. On the other hand, we have observed that different proteins 8 induce different functional profiles during acute infection, which may influence disease control¹. 9 Responses against the N protein seem to more consistently induce polyfunctional antiviral T cells and these responses may be more conserved among other coronaviruses^{1, 6, 24, 25}. Instead, S-10 specific immune responses may better support B cell and antibody generation via follicular helper 11 12 T cells, instrumental for limiting infection^{1, 5}. Thus, another conclusion would be highlighting the interest of including other proteins beyond the spike such as N sequences, which has been 13 14 suggested before^{1, 6, 19, 25, 26}. Last, in terms of duration, our study lacks longitudinal data to assess 15 the dynamics in the different compartments, yet it is assumed that T_{RM} phenotypes will contribute to long-term persistence^{1, 7, 16}. In fact, the only patient for which we had longitudinal sampling after 16 17 infection and after the third vaccine boost (extended Fig. 9) demonstrated that even if vaccination 18 fails to induce a systemic antibody response, a low frequency SARS-CoV-2 T cell response 19 directed to proteins from the original infection remains exclusively detectable in the lung as T_{RM} 20 one year after.

21 We acknowledge that our study has several limitations, including the small sample size 22 for the different groups. In addition, we addressed T cell immune responses in older and mostly 23 oncologic patients, which may overall underestimate immune responses in all groups. Whereas 24 the fact that the Inf group consisted of patients recovered from mild or severe disease, even if 25 age and underlying conditions were similar to the other groups, may have skewed frequencies of 26 SARS-CoV-2-specific T cells towards the higher end. Still, considering their age and condition, 27 any of these patients with a new infection would most likely develop a more serious COVID-19 28 event compared to the general population. In addition, the boosted Vx3 group was sampled short term comparing to the Vx2 group, but enhancement of T cell responses would be better detected 29 5-10 days after boosting^{10, 11} (which was a less likely time for scheduling surgery). Still it was 30 31 enough to suggest that there was no major enhancement of long-term durable T cell response in 32 the lung by a third boost. Further, we did not assess the contribution of T cells targeting mutation 33 regions to the total spike since we aimed to compare the strength and function of vaccinated and 34 naturally infected patients (these last group obtained during the first wave). However, the overall

contribution of T cell responses to mutational regions/total spike responses has been reported to
 be low^{13, 27}. Last, low percentages of SARS-CoV-2 specific CD8⁺ T cells may be due to the use
 of 15-mer peptides, which are less optimal than 9/10-mer peptides for HLA class I binding⁴,
 although this is debatable²¹.

5 Overall, our results contribute to the understanding of disease protection mediated by 6 current mRNA vaccines. While our data indicates a more robust and broader cellular response in 7 convalescent patients, S-specific T cells can be detected in the lung of vaccinated individuals to 8 similar overall levels 8 months after immunization, highlighting the durability of this immune arm. 9 Further, while we detected increased levels of IFN γ^+ T cell responses in blood after the third dose, 10 limited benefit of boosting towards the enhancement of T cell responses in the lung was evidenced 11 by our data. However, elderly people not responding to vaccination have been shown to benefit 12 from a third dose²³ and there is an obvious benefit of boosting to provide a higher degree of 13 antibody-mediated protection from infection in the context of high incidence of VOC². Still, if virus 14 neutralization is unable to completely block infection, a more robust and wider T_{RM} response 15 established in the lung of convalescent-infected individuals may have more chances of limiting disease. The inclusion of other protein fragments such as nucleocapsid peptides^{1, 6, 19, 25, 26} in 16 combination with mucosal routes²⁸ will likely contribute to the establishment of optimal memory T 17 18 cells in future vaccine strategies.

19

20 METHODS

21 Ethics statement

This study was performed in accordance with the Declaration of Helsinki and approved by the corresponding Institutional Review Board (PR(AG)212/2020) of the Vall d'Hebron University Hospital (HUVH), Barcelona, Spain. Written informed consent was provided by all patients recruited to this study.

26

27 Subject recruitment and sample collection

Patients undergoing lung resection for various reasons at the HUVH were recruited through the Thoracic Surgery Service and invited to participate. Initially, a total of 32 patients, from whom paired blood samples and lung biopsies were collected were assayed. However, based on vaccination and/or infection status of the recruited patients, 26 (+2: HL174 and HL162) patients were finally included. Extended data Table 1 summarizes relevant information from included patients. For all participants, whole blood was collected with EDTA anticoagulant. Plasma was collected and stored at -80 °C (except for 4 patients distributed among the different groups, as

1 indicated in Extended Data Table 1, for which this sample was not available) and PBMCs were

isolated via Ficoll–Pague separation and processed immediately for stimulation assays.

2 3

4 Phenotyping and Intracellular Cytokine Staining of lung biopsies

5 Immediately following surgery, healthy areas from patients undergoing lung resection were 6 collected in antibiotic-containing RPMI 1640 medium and processed as published¹. Briefly, 8-mm³ 7 dissected blocks were first enzymatically digested with 5 mg/ml collagenase IV (Gibco) and 8 100µg/ml of DNase I (Roche) for 30 min at 37 °C and 400 rpm and, then, mechanically digested 9 with a pestle. The resulting cellular suspension was first filtered through a 70µm pore size cell 10 strainer and then filtered through a 30µm pore size cell strainer (Labclinics). After washing with 11 PBS, cells were stimulated in a 96-well round-bottom plate for 16 to 18 hours at 37°C with 1µg/mL 12 of SARS-CoV-2 peptides (PepTivator SARS-CoV-2 M. N or S. Miltenvi Biotec) in the presence of 13 3.3µL/mL α-CD28/CD49d (clones L293 and L25), 0.55µL/mL Brefeldin A, 0.385µL/mL Monensin 14 and 5 µL/100µL anti-CD107a-PE-Cy5 (all from BD Biosciences). For each patient, a negative 15 control, cells treated with medium, and positive control, cells incubated in the presence of 0.4nM PMA and 20µM lonomycin, were included. Next day, cellular suspensions were stained with 16 17 Live/Dead Agua (Invitrogen) and anti-CD103 (FITC, Biolegend), anti-CD69 (PE-CF594, BD 18 Biosciences), anti-CD40 (APC-Cy7, Biolegend), anti-CD8 (APC, BD Biosciences), anti-CD3 19 (BV650, BD Biosciences) and anti-CD45 (BV605, BD Biosciences) antibodies. Cells were 20 subsequently fixed and permeabilized using the FoxP3 Fix/Perm kit (BD Biosciences) and stained 21 with anti-IL-4 (PE-Cy7, eBioscience), anti-IL-10 (PE, BD Biosciences), anti-T-bet (BV421, 22 Biolegend) and anti-IFN γ (AF700, Invitrogen) antibodies. After fixation with PBS 2% PFA, cells 23 were acquired in a BD LSR Fortessa flow cytometer (Cytomics Platform, High Technology Unit, 24 Vall d'Hebron Institut de Recerca).

25

26 Phenotyping and Intracellular Cytokine Staining in blood

27 Freshly isolated PBMCs were labelled for CCR7 (PE-CF594, BD Biosciences) and CXCR3 28 (BV650, BD Biosciences) for 30 min at 37°C. After washing with PBS, PBMCs were stimulated in 29 a 96-well round-bottom plate for 16 to 18 hours at 37°C with 1µg/mL of SARS-CoV-2 peptides 30 together with the same concentration of Brefeldin A, Monensin, α-CD28/CD49d and CD107a-PE-31 Cy5, as stated for the lung suspension above and published before¹. For each patient, a negative 32 control and a positive control were also included. After stimulation, cells were washed twice with 33 PBS and stained with Aqua LIVE/DEAD fixable dead cell stain kit (Invitrogen). Cell surface 34 antibody staining included anti-CD3 (Per-CP), anti-CD4 (BV605) and anti-CD56 (FITC) (all from

BD Biosciences). Cells were subsequently fixed and permeabilized using the Cytofix/Cytoperm kit (BD Biosciences) and stained with anti-Caspase-3 (AF647, BD Biosciences), anti-Bcl-2 (BV421, Biolegend), anti-IL-4 (PE-Cy7, eBioscience), anti-IL-10 (PE, BD Biosciences) and anti-IFNg (AF700, Invitrogen) for 30 mins. Cells were then fixed with PBS 2% PFA and acquired in a BD LSR Fortessa flow cytometer.

6

7 SARS-CoV-2 serology

8 The serological status of patients included in this study was determined in serum samples using 9 two commercial chemiluminescence immunoassays (CLIA) targeting specific SARS-CoV-2 10 antibodies: (1) Elecsys Anti-SARS-CoV-2 (Roche Diagnostics, Mannheim, Germany) was 11 performed on the Cobas 8800 system (Roche Diagnostics, Basel, Switzerland) for the 12 determination of total antibodies (including IgG, IgM, and IgA) against nucleocapsid (N) SARS-13 CoV-2 protein; and (2) Liaison SARS-CoV-2 TrimericS IgG (DiaSorin, Stillwater, MN) was 14 performed on the LIAISON XL Analyzer (DiaSorin, Saluggia, Italy) for the determination of IgG 15 antibodies against the spike (S) glycoprotein.

16

17 **Pseudovirus neutralization assay**

18 The spike of the Omicron SARS-CoV-2 was generated (GeneArt Gene Synthesis, ThermoFisher 19 Scientific) from the plasmid containing the D614G mutation with a deletion of 19 amino acids, 20 which was modified to include the mutations specific for this VOC (A67V, Δ 69-70, T95I, 21 G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, 22 G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, 23 N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F) (kindly provided by Drs. J. 24 Blanco and B. Trinite). Pseudotyped viral stocks of VSV* $\Delta G(Luc)$ -S were generated following the 25 protocol described in²⁹. Briefly, 293T cells were transfected with 3µg of the omicron plasmid 26 (pcDNA3.1 omicron). Next day, cells were infected with a VSV-G-Luc virus (MOI=1) for 2h and 27 washed twice with warm PBS. To neutralize contaminating VSV*AG(Luc)-G particles cells were 28 incubated overnight in media containing 10% of the supernatant from the 11 hybridoma (ATCC 29 CRL-2700), containing anti-VSV-G antibodies. Next day, viral particles were harvested and 30 titrated in VeroE6 cells by enzyme luminescence assay (Britelite plus kit; PerkinElmer). For the 31 neutralization assays, VeroE6 cells were seeded in 96-well white, flat-bottom plates (Thermo 32 Scientific) at 30,000 cells/well. Plasma samples were heat-inactivated and diluted four-fold 33 towards a concentration of 1/32 of the initial sample. Diluted plasma samples were then incubated with pseudotyped virus (VSV* $\Delta G(Luc)$ -S^{omicron}) with titers of approximately 1x10⁶ – 5x10⁵ RLUs/ml 34

1 of luciferase activity - in a 96 well-plate flat bottom for 1 hour at 37°C, 5% CO₂. Next, 30,000 Vero 2 E6 cells were added to each well and incubated at 37°C, 5% CO₂ for 20-24 hours. Then, viral 3 entry was measured by the expression of luciferase. Cells were incubated with Britelite plus 4 reagent (Britelite plus kit; PerkinElmer) and then transferred to an opaque black plate. 5 Luminescence was immediately recorded by a luminescence plate reader (LUMIstar Omega). 6 Viral neutralization was calculated as the reciprocal plasma dilution (ID50) resulting in a 50% 7 reduction in relative light units. If no neutralization was observed, an arbitrary titer value of 16 (half 8 of the limit of detection [LOD]) was reported.

9

10 Statistical analyses

11 Flow cytometry data was analyzed using FlowJo v10.7.1 software (TreeStar). Data and statistical 12 analyses were performed using Prism 8.0 (GraphPad Software, La Jolla, CA, USA). Data shown 13 in bar graphs were expressed as median and Interguartile range (IQR), unless stated otherwise. 14 Correlation analyses were performed using non-parametric Spearman rank correlation. Kruskal-15 Wallis rank-sum test with Dunn's post-hoc test was used for multiple comparisons. Friedmann test with Dunn's post-hoc test was applied for paired comparisons. A P value <0.05 was 16 17 considered statistically significant. Antigen-specific T-cell data was calculated as the net 18 frequency, where the individual percentage of expression for a given molecule in the control 19 condition (vehicle) was subtracted from the corresponding SARS-CoV-2-peptide stimulated 20 conditions.

21

22 ACKNOWLEDGMENTS

23 We would like to thank all the patients who participated in the study and Drs. Julià Blanco and 24 Benjamin Trinite for providing the plasmid encoding the omicron spike. This work was supported 25 by grants from Fundació La Marató TV3 (201814-10 FMTV3 and 202112-30 FMTV3), from the 26 Health department of the Government of Catalonia (DGRIS 1_5), and the Spanish AIDS network 27 Red Temática Cooperativa de Investigación en SIDA (RD16/0025/0007). M.J.B is supported by 28 the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). The 29 funders had no role in study design, data collection and analysis, the decision to publish, or 30 preparation of the manuscript.

31

32 AUTHOR CONTRIBUTIONS

33 Conceptualization, M.G.; Patient Recruitment and Sample Collection, J.R., V.F.; Methodology,

34 DKJ.P., SG.K., A.G.R., J.R-C, C.M., J.E.; Investigation, DKJ.P., SG.K., A.G.R., J.E.; Formal

- 1 Analysis, DKJ.P., A.G.R., M.J.B. and M.G.; Writing-Original Draft, DKJ.P. and M.G; Writing-
- 2 Review & Editing, all authors; Funding Acquisition, M.G.; Supervision, M.G.
- 3

4 DECLARATION OF CONFLICT OF INTEREST

- 5 The authors declare no competing interest.
- 6

DATA AVAILABILITY

The authors declare that the data supporting the findings of this study are available within the paper and its supplementary information files.

REFERENCES

- Grau-Exposito J, Sanchez-Gaona N, Massana N, Suppi M, Astorga-Gamaza A, Perea D, et al. Peripheral and lung resident memory T cell responses against SARS-CoV-2. *Nature communications* 2021, **12**(1): 3010.
 Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *The Lancet Microbe* 2022, **3**(1): e52-e61.
 Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, et al. SARS-CoV-2 variants of
 - 3. Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, *et al.* SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. *Science immunology* 2021, **6**(59).
- 4. Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. *Nature* 2022, **603**(7901): 488-492.
- 5. Moss P. The T cell immune response against SARS-CoV-2. *Nat Immunol* 2022, **23**(2): 186-193.
- 6. Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. *Nature communications* 2022, **13**(1): 80.
- 7. Niessl J, Sekine T, Buggert M. T cell immunity to SARS-CoV-2. Seminars in immunology 2021, 55: 101505.
- Jung JH, Rha MS, Sa M, Choi HK, Jeon JH, Seok H, et al. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells. Nature communications 2021, 12(1): 4043.
- 9. Szabo PA, Dogra P, Gray JI, Wells SB, Connors TJ, Weisberg SP, *et al.* Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. *Immunity* 2021, **54**(4): 797-814 e796.
- 10. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. *Science* 2021, **374**(6572): abm0829.
- 11. Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Galvez RI, et al. Humoral and cellular immune memory to four COVID-19 vaccines. *bioRxiv : the preprint server for biology* 2022.
- 44 12. Ortega N, Ribes M, Vidal M, Rubio R, Aguilar R, Williams S, *et al.* Seven-month kinetics of SARS-CoV-2
 45 antibodies and role of pre-existing antibodies to human coronaviruses. *Nature communications* 2021, **12**(1):
 46 47

- 13. Minervina AA, Pogorelyy MV, Kirk AM, Crawford JC, Allen EK, Chou CH, *et al.* SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8 T cells. *medRxiv : the preprint server for health sciences* 2022.
- 14. Sheikh-Mohamed S, Isho B, Chao GYC, Zuo M, Cohen C, Lustig Y, *et al.* Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. *Mucosal immunology* 2022.
- 15. Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, *et al.* A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. *Cell* 2020, **183**(1): 169-184 e113.
- 16. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. *Immunologic research* 2014, **59**(1-3): 118-128.
- 17. Le Bert N, Clapham HE, Tan AT, Chia WN, Tham CYL, Lim JM, *et al.* Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. *The Journal of experimental medicine* 2021, **218**(5).
- Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* 2020, 181(7): 1489-1501 e1415.
- 19. Taus E, Hofmann C, Ibarrondo FJ, Hausner MA, Fulcher JA, Krogstad P, *et al.* Dominant CD8(+) T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination. *Front Immunol* 2022, **13:** 835830.
- 20. Demaret J, Lefevre G, Vuotto F, Trauet J, Duhamel A, Labreuche J, et al. Severe SARS-CoV-2 patients develop a higher specific T-cell response. *Clinical & translational immunology* 2020, **9**(12): e1217.
- 21. Thieme CJ, Anft M, Paniskaki K, Blazquez-Navarro A, Doevelaar A, Seibert FS, et al. Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients. *Cell reports Medicine* 2020, **1**(6): 100092.
- 22. Poon MML, Byington E, Meng W, Kubota M, Matsumoto R, Grifoni A, et al. Heterogeneity of human antiviral immunity shaped by virus, tissue, age, and sex. *Cell reports* 2021, **37**(9): 110071.
- 23. Romero-Olmedo AJ, Schulz AR, Hochstatter S, Das Gupta D, Virta I, Hirseland H, et al. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults. *Nature microbiology* 2022, **7**(2): 195-199.
- 24. Matchett WE, Joag V, Stolley JM, Shepherd FK, Quarnstrom CF, Mickelson CK, *et al.* Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity. *Journal of immunology* 2021, **207**(2): 376-379.
- 25. Peng Y, Felce SL, Dong D, Penkava F, Mentzer AJ, Yao X, et al. An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nat Immunol 2022, **23**(1): 50-61.
- Mazzoni A, Di Lauria N, Maggi L, Salvati L, Vanni A, Capone M, et al. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. The Journal of clinical investigation 2021, 131(12).
- 27. Skelly DT, Harding AC, Gilbert-Jaramillo J, Knight ML, Longet S, Brown A, *et al.* Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. *Nature communications* 2021, **12**(1): 5061.
- 58 28. Mao T, Israelow B, Suberi A, Zhou L, Reschke M, Pena-Hernandez MA, et al. Unadjuvanted intranasal spike
 59 vaccine booster elicits robust protective mucosal immunity against sarbecoviruses. bioRxiv : the preprint
 60 server for biology 2022.

29. Grau-Exposito J, Perea D, Suppi M, Massana N, Vergara A, Soler MJ, et al. Evaluation of SARS-CoV-2 1 2 3 4 entry, inflammation and new therapeutics in human lung tissue cells. PLoS pathogens 2022, 18(1): e1010171.

FIGURE LEGENDS

1

2 Fig. 1. SARS-CoV-2-specific T-cell responses in peripheral blood from convalescent and 3 vaccinated patients. (a) Representative flow-cytometry plots showing CD4⁺ T cells expressing 4 CD107a and IFNy after exposure of whole PBMCs to S-peptide pools or left unstimulated for each 5 of the four groups included in this study (complete gating strategy is shown in Extended Data Fig. 6 2a). (b) Comparison of the net frequency (background subtracted) of IFN γ^+ cells within CD4⁺ 7 (upper) and CD8⁺ (lower) T-cell subsets after stimulation of PBMCs with any of the three viral 8 peptide pools (membrane (M), nucleocapsid (N) and spike (S) peptides). Data are shown as 9 median \pm IQR, where each dot represents an individual patient for each group (Ctrl, control, n=5: 10 Inf, convalescent infected, n=9; Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3 doses, n=5). 11 Statistical significance was determined by Kruskal-Wallis test (with Dunn's post-test).

12

13 Fig. 2. SARS-CoV-2-specific lung T-cell responses from convalescent and vaccinated

14 patients and comparison between tissue compartments. (a) Representative flow-cytometry

15 plots showing CD4⁺ T cells expressing CD107a and IFNγ after exposure of single-cell

16 suspensions of lung tissue to S-peptide pools or left unstimulated for each of the four groups

17 included in this study (complete gating strategy is shown in Extended Data Fig. 2b). (b)

18 Comparison of the net frequency (background subtracted) of IFN γ^+ cells within CD4⁺ (upper) and

19 CD8⁺ (lower) T-cell subsets after exposure of lung single-cell suspensions to any of the three

20 viral peptide pools (membrane (M), nucleocapsid (N) and spike (S) peptides). (c) Comparison of

21 the net frequency of IFN γ^+ cells within CD4⁺ (left) and CD8⁺ (right) T-cell subsets in paired blood

22 and lung samples of each group after exposure to S-peptide pools. Data in bar graphs are

23 shown as median ± IQR, where each dot represents an individual patient for each group (Ctrl,

24 control, n=5; Inf, convalescent infected, n=9; Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3

25 doses, n=5). Statistical significance was determined by (b) Kruskal-Wallis test (with Dunn's

26 post-test) or (c) Friedmann test (with Dunn's post-test).

27

Fig. 3. Frequency of Spike-specific T_{RM} **cells in the lung.** (a) Representative flow-cytometry plots showing three subsets of CD4⁺ T cells present in the lung: CD69⁻ non-T_{RM}, CD69⁺ T_{RM}, and CD69⁺CD103⁺ T_{RM} cells expressing CD107a and IFN_Y after exposure of single-cell suspensions of lung tissue to S-peptide pools or left unstimulated for an Inf and a Vx2 patients. (b) Comparison of the net frequency of S-specific IFN_Y⁺ cells within the three (non-) T_{RM} cell subsets present in

the lung for each group. Data in bar graphs are shown as median \pm IQR, where each dot represents an individual patient for each group (Ctrl, control, n=5; Inf, convalescent infected, n=8; Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3 doses, n=4). Statistical significance was determined by Friedmann test (with Dunn's post-test) for the difference between the cellular subsets within each patient group.

6

7 Fig. 4. Overall functional T-cell response of lung and blood compartments. (a, b) Donut 8 charts displaying the net contribution of each functional marker (IFN γ , CD107a, IL-4, and IL-10) 9 to the overall S-specific CD4⁺ (a) and CD8⁺ (b) T-cell response within the lung resident and non-10 resident T-cell subsets and in peripheral blood for each of the individual patient groups. Data 11 represent the mean value of the net frequency of each function within the patient group, including 12 both responders and non-responders. The frequency shown inside each donut chart represents 13 the accumulated mean response of all functions. Bar charts on the right show the mean of the 14 total frequency considering all functions per group (mean ± SD). Statistical significance was 15 determined by Kruskal-Wallis test (with Dunn's post-test) for the difference between each group. 16 * P < 0.05.

17

18 Fig. 5. Polyfunctional CD4⁺ and CD8⁺ T-cell responses in blood and lung of convalescent 19 and vaccinated patients. (a, b) Comparison of the net frequency of polyfunctional CD107a⁺ 20 IFN γ^+ cells within CD4⁺ and CD8⁺ T-cell subsets for each of the four groups after exposure of 21 PBMCs (a) or single-cell suspensions of lung tissue (b) to any of the three viral peptide pools 22 (membrane (M), nucleocapsid (N) and spike (S) peptides). Data in bar graphs are shown as 23 median \pm IQR, where each dot represents an individual patient for each group (Ctrl, control, n=5; 24 Inf, convalescent infected, n=9; Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3 doses, n=5). 25 Statistical significance was determined by was determined using Kruskal-Wallis test (with Dunn's 26 post-test).

- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34

1 EXTENDED DATA LEGENDS

2

3 Extended Data Fig. 1. Correlation between SARS-CoV-2-specific antibodies, neutralizing 4 capacity, age, and sampling time. Graphs show the relationship between: (a) S-specific IgG 5 antibodies (AU/mL) in plasma and SARS-CoV-2 neutralization titer for each group (Inf. 6 convalescent infected, n=7; Vx2, vaccine 2 doses, n=6 and Vx3, vaccine 3 doses, n=4); (**b**, **c**) 7 SARS-CoV-2 neutralization titer and age of Inf patients (b) and Vx2 patients (c); (d, e) S-specific 8 IgG antibodies (AU/mL) and age of Inf patients (d) and Vx2 patients (e); (f) S-specific IgG 9 antibodies (AU/mL) in all groups and day of sampling after infection or vaccination; and (e) N-10 specific Ig antibodies (index) in Inf patients and day of sampling after infection. Correlations (r and 11 P values) were assessed by Spearman test.

12

Extended Data Fig. 2. Gating strategy for the analysis of T cells present in peripheral blood and lung tissue. (a, b) Representative flow-cytometry plots showing the gating strategy towards the identification of CD4⁺ and CD8⁺ T cells within PMBC (a) and lung tissue (b) samples. CD4⁺ and CD8⁺ T-cell subsets in PBMCs were identified by gating of time (to exclude disturbances in flow measurements), followed by gating of total lymphocytes, single cells, and live cells. CD4⁺ and CD8⁺ T-cell subsets in lung tissue were identified by gating of time, live CD45⁺ cells, single cells, and lymphocytes.

20

21 Extended Data Fig. 3. Spike-specific T-cell responses (CD107a, IL-4, IL-10) in peripheral 22 blood from convalescent and vaccinated patients. Comparison of the net frequency of 23 CD107a⁺ (left), IL-4⁺ (middle), and IL-10⁺ (right) cells within CD4⁺ (upper) and CD8⁺ (lower) T-cell 24 subsets for each of the four groups after exposure of PBMCs to S-peptide pools. Data in bar 25 graphs are shown as median \pm IQR, where each dot represents an individual patient for each 26 group (Ctrl, control, n=5; Inf, convalescent infected, n=9; Vx2, vaccine 2 doses, n=7 and Vx3, 27 vaccine 3 doses, n=5). Statistical significance was determined by Kruskal-Wallis test (with Dunn's 28 post-test).

29

Extended Data Fig. 4. SARS-CoV-2-specific T-cell responses (CD107a, IL-4, IL-10) in the lung from convalescent and vaccinated patients. (a) Comparison of the net frequency of $CD107a^+$ (left), IL-4⁺ (middle), and IL-10⁺ (right) cells within CD4⁺ (upper) and CD8⁺ (lower) T-cell subsets for each of the four groups after exposure of single-cell suspensions of lung tissue to Speptide pools. Data in bar graphs are shown as median \pm IQR, where each dot represents an

1 individual patient for each group (Ctrl, control, n=5; Inf, convalescent infected, n=9; Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3 doses, n=5). Statistical significance was determined by Kruskal-3 Wallis test (with Dunn's post-test). (**b**) Correlation between the net frequency of S-specific 4 CD107a⁺ cells of CD4⁺ (left) and CD8⁺ (right) T cells in the lung and age (Inf group). Correlations 5 (*r* and *P* values) were assessed by Spearman test.

6

Extended Data Fig. 5. Comparison of the frequency of S-peptide specific CD4⁺ and CD8⁺ T cells between lung and blood. (a-c) Graphs show the individual patient net frequency of CD107a⁺ (a), IL-4⁺ (b), and IL-10⁺ (c) cells within CD4⁺ (left) and CD8⁺ (right) T-cell subsets of paired blood and lung samples that were exposed to S-peptide pools. Statistical significance was determined using Friedmann test (with Dunn's post-test) for the difference between blood and lung samples within each patient group.

13

14 Extended Data Fig. 6. The response of CD4⁺ and CD8⁺ (non-) T_{RM} cells against M and N 15 **peptide pools.** (a, b) Comparison of the net frequency of IFN γ^+ cells within three T_{RM}-cell subsets 16 of CD4⁺ (left) and CD8⁺ (right) T cells present in the lung: CD69⁻ non-T_{RM}, CD69⁺ T_{RM}, and 17 CD69⁺CD103⁺ T_{RM} cells for each group after exposure to (a) M- and (b) N-peptide pools. Data in 18 bar graphs are shown as median \pm IQR, where each dot represents an individual patient for each 19 group (Ctrl, control, n=5; Inf, convalescent infected, n=8; Vx2, vaccine 2 doses, n=7 and Vx3, 20 vaccine 3 doses, n=4). Statistical significance was determined using Friedmann test (with Dunn's 21 post-test) for the difference between the cellular subsets within each patient group. (c) Correlation 22 between the net frequency of lung S-specific IFN γ^+ cells within the CD8⁺ CD69⁺ CD103⁺ T_{RM} 23 subset and days since confirmed infection and sampling (Inf group). (d) Correlation between the 24 net frequency of S-specific CD107a⁺ CD8⁺ CD69⁺ CD103⁺ T_{RM} cells or CD8⁺ CD69⁺ T_{RM} cells and 25 age (Inf group). Correlations (r and P values) were assessed by Spearman test.

26

Extended Data Fig. 7. Frequency of polyfunctional T-cell responses against spike with a tissue-resident phenotype in the lung. Comparison of the net frequency of S-specific polyfunctional CD107a⁺ IFN γ^+ cells within lung CD4⁺ (upper) and CD8⁺ (lower) (non-) tissueresident cell subsets (CD69⁻ non-T_{RM}, CD69⁺ T_{RM}, and CD69⁺CD103⁺ T_{RM} cells) for each of the four patient groups after exposure of single-cell lung suspensions to S-peptide pools. Data in bar graphs are shown as median ± IQR, where each dot represents an individual patient for each group (Ctrl, control, n=5; Inf, convalescent infected, n=8; Vx2, vaccine 2 doses, n=7 and Vx3,

vaccine 3 doses, n=4). Statistical significance was determined by Kruskal-Wallis test (with Dunn's
 post-test) for the difference between the groups.

3

4 Extended Data Fig. 8. T-cell responses for patient #174. (a) Timeline for patient 174, indicating 5 vaccination against SARS-CoV-2, infection with SARS-CoV-2, and acquisition of blood and lung 6 samples. (b) Donut charts displaying the net contribution of each functional marker (IFNy, 7 CD107a, IL-4, IL-10, or no response) to the M-, N-, and S-specific CD4⁺ and CD8⁺ T-cell response 8 within the lung resident and non-resident T-cell subsets and in peripheral blood for patient 174. 9 The frequency shown inside each donut chart represents the accumulated mean response of all 10 functions. (c) Flow-cytometry plots of patient 174 showing CD4⁺ (upper) and CD8⁺ (lower) T cells 11 expressing CD107a and IFN γ after exposure of lung single-cell suspensions (left) and PBMCs 12 (right) to M-, N- and S-peptide pools or left unstimulated. 13

14 Extended Data Fig. 9. T-cell responses for patient #162. longitudinal samples. (a) Timeline 15 for patient 162 who was longitudinally sampled, first ~4 months after SARS-CoV-2 infection and 16 then ~1 month after third dose mRNA-vaccination. (b, c) Donut charts displaying the net 17 contribution of each functional marker (IFN_γ, CD107a, IL-4, IL-10, or no response) to the M-, N-, 18 and S-specific CD4⁺ and CD8⁺ T-cell response within the lung resident and non-resident T-cell 19 subsets and in peripheral blood for patient 162 in the first sample (b) and second sample (c). The 20 frequency shown inside the donut chart represents the accumulated mean response of all 21 functions.

22

23 Extended Data Fig. 10. Longitudinal patterns of SARS-CoV-2-specific T-cell responses in

24 **lung and blood for patient #162. (a, b)** Flow-cytometry plots showing longitudinal data (left, after

25 infection, sample 1; right, after third-dose vaccination, sample 2) of patient 162 showing CD4⁺

26 (top) and CD8⁺ (bottom) T cells expressing CD107a and IFNγ after exposure of PBMCs (**a**) and

27 lung cell suspension (b) to M-, N-, and S-peptide pools or left unstimulated (vehicle).

Extended Table 1. Patient characteristics

	Control	Infected	Vx2	Vx3	P value
	n=5	n=9‡	n=7‡	n=5‡	between groups
Age (Years), median [IQR]	67 [66-74]	69 [65-71]	61 [58-70]	72 [69-73]	0.6555ª
Female, n (%)	1/5 (20%)	1/9 (11%)	4/7 (57%)	3/5 (60%)	0.0875 ^b
Days after infection* or vaccination, median [IQR]	N/A	304 [183-320]	206 [184-234]	52 [42-54]	0.0006ª
Spike-specific IgG** (AU/mL), median [IQR] (AU/mL)	<1.85 [1.85-1.85]	133.1 [89.04-228.46]	225 [118.85-248.46]	800 [716,35-800]	0.0122ª
Total nucleocapsid-specific Ig** (Index), median [IQR]	0.07 [0.07-0.08]	135 [62.1-157.5]	0.1 [0.07-0.11]	0.1 [0.06-0.09]	0.0001ª
Virus neutralization titer***, median [IQR]	0 [0-0]	40 [19-56]	50 [46.25-471.5]	138.5 [67.75-665.75]	0.0974ª
Patients with SARS-CoV-2 neutralization capacity, n (%)	0/5 (0%)	5/7 (71%)	5/6 (83%)	4/4 (100%)	0.4877 ^b
New infection after sampling, n (%)	0/5 (0%)	0/9 (0%)	1/7 (14%)	0/5 (0%)	0.3763 ^b

* Confirmed by RT-PCR for SARS-CoV-2

** Measured by anti-SARS-CoV-2 S and N immunoassay

*** Measured by SARS-CoV-2 neutralization assay

‡ Plasma samples were not available for every patient

N/A not available

^a Kruskal-Wallis test with Dunn's post-test

^b Chi-square test

Figure 1



Figure 2









а



b





















medRxiv preprint doi: https://doi.org/10.1101/2022.05.25.22275300; this version posted May 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.













b

Lung

